profit from every $100 of sales.
$0$100
IDEAYA Biosciences
$32.72+3.04% today
+2.2% in 1 year
1-year low $27.601-year high $42.48
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What IDEAYA Biosciences sold, what it kept, and what it did with the cash.
Sales went from $50.9 million in 2022 to $219 million in 2025, with -$114 million of profit last year.
SalesProfit
IDEAYA Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| IDEAYA Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads IDEAYA Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 51 | 23 | 7 | 219 | |
| – | – | – | – | |
| -63 | -134 | -327 | -159 | |
| -59 | -130 | -323 | -155 | |
| -59 | -113 | -274 | -114 | |
| -1.42 | -1.96 | -3.36 | -1.28 | |
| – | – | – | – | |
| -122.7% | -574.9% | -4,671.1% | -72.8% | |
| -115.2% | -483.0% | -3,921.1% | -52.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 388 | 649 | 1,124 | 1,109 |
| Cash | 69 | 157 | 84 | 113 |
| Total debt | 3 | 3 | 19 | 28 |
| Total liabilities | 39 | 28 | 65 | 86 |
| 349 | 621 | 1,059 | 1,023 | |
| 41 | 58 | 82 | 88 | |
| -14.0% | -17.0% | -24.0% | -12.0% | |
| -16.8% | -18.2% | -25.9% | -11.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -87 | -115 | -248 | -71 | |
| 3 | 2 | 4 | 2 | |
| -91 | -118 | -251 | -73 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 12 | 18 | 35 | 46 |
Valuation
- –
- –
- –
- 2.8×
- 14.5×
- –
- –
- -2.3%
- -3.6%
- 0.0%
Profitability
- 99.5%
- -72.8%
- -52.0%
- -79.4%
- -19.0%
- -17.4%
- -14.0%
- -13.6%
- -19.0%
- 150.7%
Growth
- +62.5%
- –
- +70.8%
- –
- +25.9%
Financial health
- -0.5×
- 0.03
- 2.8%
- –
- 10.74
- 10.74
- 0.22
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 959
Bottom 5%of 888
Top 9%of 889
Bottom 27%of 987
What analysts expect
- Average price target
- $58.67
- Range
- $53.00 – $65.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -1.11 | -1.07 | −3.7% |
| Feb 17, 2026 | -0.94 | -0.95 | +1.2% |
| Nov 4, 2025 | 1.33 | -0.95 | +240.6% |
| Aug 5, 2025 | -0.88 | -0.85 | −3.5% |
| May 6, 2025 | -0.82 | -0.75 | −9.3% |
| Feb 13, 2025 | -1.49 | -0.67 | −122.4% |
| Nov 4, 2024 | -0.60 | -0.67 | +10.4% |
| Aug 6, 2024 | -0.68 | -0.55 | −23.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
45No pass
Philip Fisher
49No pass
Peter Lynch
73Pass
Joel Greenblatt
2No pass
Charlie Munger
36No pass
Terry Smith
38No pass
Questions about IDEAYA Biosciences
Is IDEAYA Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the IDEAYA Biosciences AI analysis
What does IDEAYA Biosciences do?
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is in Biotechnology, based in South San Francisco, CA, United States, with 145 employees.
Does IDEAYA Biosciences pay a dividend?
No. IDEAYA Biosciences does not pay a dividend at the moment.
Is IDEAYA Biosciences stock halal?
Yes. IDEAYA Biosciences passes our halal screen: its business is permitted and its debt is 0.9% of its market value, under the 30% limit. How we check
How has IDEAYA Biosciences stock done over the past year?
Up 2.2% over the past twelve months, to $32.72. It traded between $27.60 and $42.48 and is 23.0% below its high.
Who are IDEAYA Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with IDEAYA Biosciences's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.